Recognizing that animal testing for drugs, cosmetics and other products is cruel, expensive and inefficient, firms are moving increasingly toward 3D printed alternatives.  L'Oreal, for example, has begun 3D printing human skin cells to test its cosmetics.

Now n3D is collaborating with L C Sciences and AstraZeneca to create a way to evaluate drug effectiveness on blood vessel constriction and dilation using 3D printed tissue cultures.  According to the 3D Printing Industry article, initial results are promising...

n3D President and CSO Dr. Glauco Souza added: ‘The speed and throughput of our vasoactivity assay sets us apart from other 3D cell culturing and 3D bioprinting techniques, such as the ones from Insphero and Organovo. We are looking forward to this assay becoming the standard in compound toxicity testing and in the development of new vasoactive drugs.’

While this particular technique appears to be focused specifically on "vasoactivity studies," it moves companies one step closer to eliminating animal testing altogether.